The phrase "accepted effectiveness" is correct and usable in written English.
It can be used in contexts where you are discussing the recognized or acknowledged efficacy of a method, treatment, or intervention.
Example: "The study demonstrated the accepted effectiveness of the new drug in treating the condition."
Alternatives: "recognized efficacy" or "acknowledged effectiveness."
Public debate over the safety of the trivalent measles, mumps and rubella (MMR) vaccine and the drop in vaccination rates in several countries persists despite its almost universal use and accepted effectiveness.
(MoPH senior manager-level 4 ) Reasons given for donor commitment to the BPHS included donor involvement in development (i.e. felt ownership), outcome-oriented design and measurement, and accepted effectiveness of selected interventions (e.g. emergency obstetric care).
But beyond these age-groups, in most scenarios, the cost-effectiveness ratios remain below the commonly accepted cost-effectiveness threshold in the immunocompetent population aged 50 years and more.
Due to the base case ICER being well below the generally accepted cost-effectiveness threshold, most analyses assessed the detrimental impact of a particular scenario on the ICER.
The overall base case incremental cost per QALY is well above the accepted cost-effectiveness threshold.
Given that currently accepted cost-effectiveness models for DMARDs do not include joint replacement as an endpoint gives added weight to the utility of these findings.
This suggests that within a 2-year time horizon the surgical therapy program is below the currently accepted cost-effectiveness threshold.
The probability of reaching the accepted cost-effectiveness threshold of GBP£20,000 to £30,000 per QALY is extremely low for the overall base case utilising an AHA or Fitness Instructor, but much more encouraging for women only.
Comparison to the accepted cost-effectiveness thresholds of $40,000 $50,000 per QALY gained and £20,000 per QALY gained in Canada and the UK respectively, suggests a high likelihood of cost-effectiveness in both countries, especially Canada, notwithstanding uncertainty in rates of outcomes and costs.
One, which was carried out using data from the SPS, and a commonly accepted cost-effectiveness threshold of $50,000 per quality-adjusted life year gained, was presented at the ACIP's 2006 meeting; it demonstrated that vaccination is cost-effective for immunocompetent adults age 60 and older (Pellisier 2006).
The ICER of GBP£51,483 per QALY for the base case analysis was well above the accepted cost-effectiveness threshold of GBP£20,000 to £30,000 per QALY, but in a sensitivity analysis with minimised program implementation the incremental cost reached GBP£25,678 per QALY.
